RT Journal Article
SR Electronic
T1 Clinically relevant shifts in endogenous and exogenous mutational processes proximate to metastasis support local consolidative treatment in EGFR-driven non-small cell lung cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.04.21256425
DO 10.1101/2021.05.04.21256425
A1 Fisk, J. Nicholas
A1 Mahal, Amandeep R.
A1 Dornburg, Alex
A1 Gaffney, Stephen G.
A1 Aneja, Sanjay
A1 Contessa, Joseph N.
A1 Rimm, David
A1 Yu, James B.
A1 Townsend, Jeffrey P.
YR 2021
UL http://medrxiv.org/content/early/2021/05/04/2021.05.04.21256425.abstract
AB The progression of cancer—including the acquisition of therapeutic resistance and the fatal metastatic spread of therapy-resistant cell populations—is an evolutionary process that is challenging to monitor between sampling timepoints. Here we apply mutational signature analysis to clinically correlated cancer chronograms to detect and describe the shifting mutational processes caused by both endogenous (e.g. mutator mutation) and exogenous (e.g. therapeutic) factors between tumor sampling timepoints. In one patient, we find that cisplatin therapy can introduce mutations that increase the likelihood of genetic adaptation to subsequent targeted therapeutics. In another patient, we trace the emergence of known driver mutation CTNNB1 S37C to specific detection of defective mismatch repair associated mutational signature SBS3. Metastatic lineages were found to emerge from a single ancestral lineage arising during therapy—a finding that argues for the consideration of local consolidative therapy over other therapeutic approaches in EGFR-positive non-small cell lung cancer. Broadly, these results demonstrate the utility of phylogenetic analysis that incorporates clinical time course and mutational signature detection to inform clinical decision making and retrospective assessment of disease etiology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJPT and DR acknowledges Gilead Sciences, Inc, for funding supporting this research, as well as the Elihu endowment and the Notsew Orm Sands Foundation. JNF acknowledges NLM Grant 5T15LM007056-32 and NCI Grant 1F31CA257288-01.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The tissues assessed in this study were obtained from the Yale Pathology Archives based on Yale Human Investigation Committee at Yale University, Protocol no. 0304025173 to Dr. David L. Rimm, which enabled retrieval of tissue from archives that was consented or had been approved for use with waiver of consent. Clinical information was retrospectively obtained for this investigation from electronic medical records after approval from the Yale University Human Investigation Committee (HIC 1508016314).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInput files for phylogenetic analyses, as well as other code, intermediate files, and diagnostic images are available at https://github.com/Townsend-Lab-Yale/LUAD-PhyLCT. The sequencing reads have been made publicly available through the NCBI Sequence Read Archive, published under the BioProject accession PRJNA674368 on November 3rd, 2020. https://github.com/Townsend-Lab-Yale/LUAD-PhyLCT https://www.ncbi.nlm.nih.gov/bioproject/PRJNA674368